Gal Wald

Dec 6, 2024 | urologytimes.com | Gal Wald

In this video, Gal Wald, MD, shares the background and rationale for the study, “Initial Results Of A Phase II Trial Of Bacillus Calmette-Guérin (BCG) And Intravesical Gemcitabine For Patients With BCG-Exposed High-Grade Non-Muscle Invasive Bladder Cancer (NCT04179162),” which he presented at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Wald is a fourth year urology resident at Weill Cornell Medicine in New York, New York.

Apr 28, 2024 | goldjournal.net | Sofia Gereta |Perioperative Care |Aaron Laviana |Gal Wald

Footnotes1 Both authors contributed equally to the publication of this manuscriptAffiliationsDepartment of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA